|
Blazar Laboratory
Bruce R. Blazar, M.D., is a Professor of Pediatrics and Chief of the Pediatric Blood and Marrow Transplantation Program. He has directed preclinical basic and translational immunology and stem cell research and early phase clinical studies for more than 20 years, with particular emphasis in the blood and marrow transplantation immunobiology.
Educational Background
- B.S., Biology, Rensselaer Polytechnic Institute, Troy, N .Y., 1972 - 1978
- M.D., Medicine, Albany Medical College, Albany, NY, 1974 - 1978
- Intern, Resident, Chief Resident, Pediatrics, University of Minnesota, Minneapolis, MN, 1978 - 1981
- Postdoctoral Fellow, Pediatric Hematology, Oncology, and Bone Marrow Transplantation, University of Minnesota, 1982 - 1984
- Postdoctoral Research Associate, Pediatrics, University of Minnesota, 1985
Professional Background
- Instructor, Pediatrics, University of Minnesota, 1985 - 1986
- Assistant Professor, Pediatrics, University of Minnesota, 1986- 1989
- Associate Professor, Pediatrics, University of Minnesota, 1989 - 1995
- Professor, Pediatrics, University of Minnesota, 1995- present
- Associate Director, University of Minnesota, Pediatric Blood and Bone Marrow Transplantation, 1994 - 2005
- Chief, Pediatric Blood and Bone Marrow Transplant New Program, University of Minnesota, 2005 - present
- Member, Microbiology, Immunology and Cancer Biology Program, 1989 - present
- Member, University of Minnesota Center for Immunology, 1993 - present
- Member, University of Minnesota Cancer Center, 1994 - present
- Member, University of Minnesota Stem Cell Institute, 2005 - present
- Member, Molecular, Cellular, and Development Biology and Genetics Program, 2007-
Professional Honors
- B.S. cum laude
- Albany Medical College Research Award 1975
- NIH National Research Service Award, 1982 - 1984
- American Cancer Society Regular Clinical Fellowship Award, 1981-1983
- Leukemia Society of America Fellowship Award, 1985 - 1987
- NIH Clinical Investigator Award, 1985 - 1990
- Member and Chair, NIH P01 and R01 Site Visit and Study Sections, 1986 - present
- Society for Pediatric Research (elected), 1988
- Member, NIH Immunobiology Study Section, July 1990 - June 1994
- Edward Mallinckrodt, Jr. Foundation Scholar Award, 1992-1995
- Vice-Chairman New Agents; Vice Chairman, Bone Marrow Transplantation, Children's Cancer Group 1992-1997
- American Society of Clinical Investigation (elected), 1996
- Chair, American Society of Blood and Marrow Transplantation scientific meeting, 1996
- Member, Transplantation Biology Subcommittee, American Society of Hematology, 1997; 2002; 2004-2008
- Member, NIH Experimental Therapeutics-2 Study Section; 1998-2002
- MERIT Award, National Heart, Lung, and Blood Institute, 1998- present
- Andersen Chair in Transplantation Immunology, 1999- present
- American Association of Blood Banks and NHLBI, Strategic Committee, Transfusion Medicine, 1999
- NHLBI and NCI, Planning Committee member for BMT State of the Science, 2000
- Member, Leukemia and Lymphoma Society Translational Grant study section, 2001- 2005
- Member, FDA Biological Response Modifiers Advisory Committee, 2001-2005
- Member, Steering Committee, Immune Tolerance Network, 2001- present
- Association of American Physicians (elected), 2002
- Member, Amer Transplant Soc, Cellular Transplant Committee (ad hoc member), 2002-2003
- Chair, NIH Cancer Immunopathology and Immunotherapy Study Section, 2003-2006
- Editorial Boards, J. Immunology; Blood; Transplantation; J. Clin. Immunol.; Biology of Blood and Marrow Transplant, Clinical Immunol and Immunopathol; Faculty of 1000
- Member, Amer. Society of Gene Therapy, Immunology Committee, 2003- present
- Visiting Professor, MD Anderson Cancer Center, 2003
- Visiting Professor, Johns Hopkins University Medical School , 2003
- James Kuebel Lecture, Washington University, 2004
- Immunology and Cancer Distinguished Lecture, Ohio State University, 2004
- Gilbert B. Forbes Visiting Scholar, University of Rochester, 2004
- Keynote Speaker, Merck, Sharp and Dohme Hematology Masterclass, London, England, 2004
- E. Donnell Thomas Lecture, American Society of Blood and Marrow Transplantation, 2005
- 2nd Annual Robertson Parkman Honorary Lectureship, 2007
- Albany Medical College, Distinguished Alumnus Lecture, 2005
- Recipient of the Distinguished Alumnus Award, Albany Medical College, 2005
- NIH Expert Panel Member, Transplantation Research, 2005
- Co-Chair, NHLBI Panel Strategic Planning for Cellular Therapies, 2005-2006
- Alpha Omega Alpha Medical Honor Society, Albany Medical College, 2006 (elected)
- Member, Pediatric Subcommittee, A State of the Science, 2006-2007
- Board of Scientific Counselors, NCI, Center for Cancer Research, November 2007-July 2012
Professional Memberships
- American Association of Immunologists
- Transplantation Society
- International Society of Experimental Hematology
- American Society of Hematology
- American Association of Cancer Research
- American Society of Blood and Bone Marrow Transplantation
- American Society of Gene Therapy
- Society for Pediatric Research, (elected)
- American Society of Clinical Investigation, (elected)
- Association of American Physicians, (elected)
- Alpha Omega Alpha, (elected)
Community and University Service
- American Cancer Society Institutional Grant Review Committee, 1986 - 1999; Chair,1989-1998
- Member, Pediatrics Tenure Track Committee Member, 1995 - Present; Chair, 1998-2007
- Pediatric Research Committee, 1995 - 1996; 2000-2003; 2005
- PRE Foundation Board, 1996 - 1998
- Pediatric Academic Planning Committtee, 2005-
- Medical Staff and Affiliations Committee, Childrens' Hospital Merger, 2006
- Cancer Center, Program Co-Leader, Transplantation Biology Program, 2004-; Executive Committee, 2004-present
Issued Patents
- Radiolabeled fusion toxins for cancer therapy. 6,001,329. December 14, 1999.
- Multimeric immunotoxins. 6,492,498. December 10, 2002
- Cell-mediated targeting of toxins to pathogenic cells; 7,101,542, September 5, 2006
- Use of a promoter of T cell activation and an inducer of CD40 stimulation in the treatment or prevention of a pathogenic state, 7,175,838, February 13, 2007
Publications (selected peer-reviewed papers, 2006-present, from a total of >350 publications)
Braunlin E, Tolar J, Berry JM, McElmurry RT, Panoskaltsis-Mortari A, Bojack SM, Clarke LA, Blazar BR: Cardiac Ultrasound and Histopathological Evaluation of the MPS I Mouse. Ped. Res. 59:27-32, 2006.
Welniak LA, Kuprash DV, Tumanov AV, Panoskaltsis-Mortari A, Blazar BR, Sun K,Nedospasov SA, Murphy WJ: The presence of Peyer’s Patches or Host-Derived TNF-a is not required for Acute Lethal Graft-versus-Host Disease after Murine Allogeneic Bone Marrow Transplantation. Blood 107:410-2, 2006
Stiff PJ, Emmanouilides C, Bensinger WI, Gentile T, Blazar BR, Shea TC, Isitt J, Lu J, Spielberger R. Palifermin (Kepivance™) Reduces Patient Reported Mouth and Throat Soreness and Improves Patient Functioning in the Hematopoietic Stem Cell Transplantation Setting. J. Clin Oncol. 33:5186-93, 2006
Huang X, Wilber A, Bao L, Tuong D, Orchard PJ, McIvor RS, Blazar BR, Zhou X: Stable gene transfer and expression in human primary T lymphocytes by Sleeping Beauty transposon system. Blood 107:483-91, 2006
Zayed H, McIvor RS, Wiest DL, Blazar BR: In Vitro Functional Correction of the Mutation Responsible for Murine Severe Combined Immune Deficiency by Short Fragment Homologous Recombination. Human Gene Therapy 17:158-66, 2006.
Steiner D, Brunicki N, Blazar BR, Bachar-Lustig E, Reisner Y. Tolerance Induction By Third Party “Off-The-Shelf” CD4+C25 u Treg Cells. Experimental Hematology 34:66-71, 2006.
Kharbanda S, Panoskaltsis-Mortari A, Haddad IY, Blazar BR, Orchard PJ, Cornfield DN, Grewal SS, Peters C, Regelmann WE, Milla CE, Baker KS: Inflammatory Cytokines and the Development of Pulmonary Complications following Allogeneic Hematopoietic Cell Transplantation in Patients with Inherited Metabolic Storage Disorders. Biol. Blood and Marrow Transplant 12:430-7, 2006.
Tolar J, O’Shaughnessy MJ, Panoskaltsis-Mortari A, McElmurry RT, Bell S, Riddle M, McIvor RS, Yant SR, Kay MA, Krause D, Verfaillie CM, Blazar BR. Host Factors that Impact the Biodistribution and Persistence of Multipotent Adult Progenitor Cells. Blood 107:4182-8, 2006
Gao N, Schwartzberg P, Wilder JA, Blazar BR, Yuan D. B Cell Induction of IL-13 Expression in NK cells: Role of CD244 and SLAM-associated protein. J. Immunol. 176:2758-64, 2006
Porter SB, Liu B, Rogosheske J, Levine B, June C, Wagner J, Miller JS, Blazar BR: Effects of graft-versus-host disease prophylactic agents on umbilical cord blood derived human CD4+CD25+ T-regulatory cells and CD4+25- T-cells expansion and function. Transplantation 82:23-29, 2006.
Subramanian IV, Nguyen TMB, Truskinovsky AM, Tolar J, Blazar BR, Ramakrishnan S. Adeno-associated virus mediated delivery of a mutant endostatin in combination with carboplatin treatment inhibits orthotopic growth of ovarian cancer and improves long-term survival. Cancer Research 66:4319-28, 2006
Barao I, Hanash AM, Welniak L, Sun K, Blazar BR, Levy R, Murphy WJ: Suppression of NK cell mediated bone marrow rejection by regulatory T cells: Linking adaptive to innate responses. ProcNatl. Acad. Sci. USA (Track II) 103:5460-5, 2006.
Eventov-Friedman S, Tchorsh D, Katchman H, Shezen E, Aronovich A, Hecht G, Dekel B, Rechavi G, Blazar BR, Feine I, Tal O, Freud E, Reisner Y.: Embryonic pig pancreatic tissue transplantation for the cure of diabetes. PLoS Medicine 7: 1165-76, 2006.
Weigel BJ, Panoskaltsis-Mortari A, Diers M, Lees C, Krieg AM, Chen W, Blazar BR: Dendritic Cells Pulsed or Fused with AML Cellular Antigen Provide Comparable Anti-Tumor Protective Response. Experimental Hematol. 34:1403-12, 2006
Blasér BW, Schwind NR, Karol S, Chang D, Shin S, Roychowdhury S, Becknell B, Ferketich AK, Kusewitt DR, Blazar BR, Caliguiri MA. Trans-Presentation of Donor-Derived Interleukin 15 is Necessary for the Rapid Onset of Acute Graft Versus Host Disease but not for Graft Versus Tumor Activity. Blood 108:2463-9, 2006
Grzywacz B, NKataria N, Sikora M, Oostendorp RA, Dzierzak EA, Blazar BR, Miller JS, Verneris MR: Coordinated acquisition of inhibitory and activating receptors and functional properties by developing natural killer cells. Blood 108:3824033, 2006.
Blazar BR, Weisdorf DJ, DeFor TE, Goldman A, Silver S, Ferrara JL: Blazar BR, Weisdorf DJ, DeFor TE, Goldman A, Braun T, Silver S, Ferrara JLM:APhase I/II Randomized, Placebo Control Trial of Palifermin to Prevent Graft-Versus-Host Disease (GVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). Blood 108:3216-22, 2006.
Steiner D, Brunicki N, Bachar-Lustig E, Taylor PA, Blazar BR, Reisner Y: Overcoming T cell mediated rejection of bone marrow allografts by T-regulatory cells: synergism with veto cells and rapamycin. Experimental Hematology 34:802-8, 2006
Taylor PA, Ehrhardt MJ, Roforth MM, Swedin JM, Panoskaltsis-Mortari A, Serody JS, Blazar BR: Preformed Antibody, Not Primed T Cells, is the Initial and Major Barrier to Bone Marrow Engraftment in Allosensitized Recipients. Blood 109:1307-15, 2007 (commentary. Fowler DH: B-ware of allosensitized graft rejection. Blood 109:851-2, 2007)
MacMillan ML, Couriel D, Weisdorf DJ, Schwab G, Havrilla N, Fleming T, Huang S, Roskos L, Slavin S, Shadduck R, DiPersio J, Territo M, Pavletic S, Linker C, Heslop HE, Deeg HJ, Blazar BR.A Phase II/III Multi-Center Randomized Clinical Trial of ABX-CBL Versus ATG as Second Line Therapy in Patients with Steroid-Resistant Acute Graft-Versus-Host Disease. Blood 109:2657-62, 2007
Tolar J, Osborn MJ, Panoskaltsis-Mortari A, McElmurry RT, Bell S, Xia L, Riddle M, Schroeder TM, Westendorf J, McIvor RS, Oseth L, Hirsch B, Yant SR, Kay MA, Peister A, Prockop D, Blazar BR. Osteosarcoma derived from gene modified mesenchymal stem cells. Stem Cells 25:371-9, 2007
Aronovich A, Tchorsch D, Katchman H, Eventov-Friedman S, Shezen E, Martinowitz U, Blazar BR, Cohen S, Tal O, Reisner Y. Correction of hemophilia as a proof of concept for treatment of monogenic diseases by fetal spleen transplantation. Proc. National Acad. Of Sciences, USA, 103: 19075-80, 2006
Min D, Panoskaltsis-Mortari A, Lacey D, Farrell C, Kuro-o M, Blazar BR, Weinberg K. Keratinocyte growth factor (KGF) treatment enhances thymopoietic capacity and immune responses in aged mice. Blood 109: 2529-37, 2006
Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Kazzaz Z, Lambotte O, Altman D, Blazar BR, Rodriguez B, Landay A, Spritzler J, Martin J, Hecht R, Picker LJ, Lederman M, Deeks S, Douek DC. Microbial Translocation and Immune Activation: Consequences of Mucosal Damage in HIV Infection. Nat. Med 12:1365-71, 2006.
Burchill MA, Yang J,Vogtenhuber C, Blazar BR, Farrar MA: Distinct roles for interleukin-2 and interleukin-15 in interleukin-2 receptor b dependent regulatory T cell development, homeostasis and function. J. Immunol 178:280-90, 2007.
Markova M, Barker JN, Miller JS, Arora M, Wagner JE, Burns LJ, MacMillan ML, Douek D, DeFor T, Tan Y, Repka T, Blazar BR, Weisdorf DJ. Fludarabine versus Cladribine When Added to Busulfan Plus Low-Dose TBI as Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: A Prospective Randomized Trial. Bone Marrow Transplant 39:193-9, 2007
Serafini M, Dylla SJ, Oki M, Heremans Y, Tolar J, Jiang J, Buckley SM, Pelacho B, Burns TC, Frommer S, Rossi DJ, Bryder D, Panoskaltsis-Mortari A, O’Shaughnessy MJ, Nelson-Holte M, Fine GC, Weissman IL, Blazar BR, Verfaillie CM. Hematopoietic Reconstitution by Multipotent Adult Progenitor Cells: Precursors to Long-Term Hematopoietic Stem Cells that can be Expanded In Vitro. J. Exp. Med. 204:129-39, 2007 (commentary. Williams R. Cell replacement therapy-are MAPCs the answer. J. Exp. Med. 204: 4, 2007)
Yun G, Tolar J, Noreen H, Blazar BR, Miller JS. A Novel Method for KIR Ligand Typing by Pyrosequencing to Predict NK Cell Alloreactivity. Clin Immunol. 123: 272-80, 2007
Tolar J, Wang X, Braunlin E, McElmurry RT, Nakamura Y, Bell S, Xia L, Zhang J, Zhang J, Blazar BR: Cardiomyoplasty with Multipotent Adult Progenitor Cells after Ischemic Injury in Immunocompetent and Immunodeficient Mice. Experimental Hematology 35:682-90, 2006
Rossi S, Jeker L, Ueno T, Kuse S, Keller M, Zuklys S, Gudkov A, Takahama Y, Krenger W, Blazar BR, Holländer G. Keratinocyte growth factor (KGF) enhances postnatal T cell development via improvement in proliferation and function of thymic epithelial cells. Blood 109: 3803-11, 2007
O’Shaughnessy MJ, Chen Z-M, Gramaglia I, Taylor PA, Panoskaltsis-Mortari, Vogtenhuber C, Palmer E, Grader-Beck T, Boussiotis VA, Blazar BR . Elevation of Intracellular cyclic AMP in alloreactive CD4+ T cells during a primary MLR can induce long term alloantigen-specific tolerance that is sufficient to prevent GVHD lethality in vivo. Biol. Blood and Marrow Transplant 13: 530-42, 2007
Berner V, Liu H, Zhou Q, Alderson K, Sun K, Weiss JM, Back TC, Longo DL, Blazar BR , Wiltrout RH, Welniak LA, Redelman D, Murphy WJ. Interferon-gamma mediateds CD4+ T cell loss and impairs secondary anti-tumor responses after successful initial immunotherapy. Nat. Med. 13:354-60, 2007
Zayed H, Xia L, Yerich A, Yant SR, Kay MA, Puttaraju M, Mansfield G, Wiest DL, McIvor RS, Tolar J, Blazar BR. Correction of severe combined immune deficiency in multipotent adult progenitor cells by spliceosome-mediated RNA trans-splicing and sleeping beauty transposon delivery. Molec. Therapy 15:1273-9, 2007.
Seggeiss R, Lore K, Guenaga FJ, Pittaluga S, Mattapallil J, Chow CK, Koup RA, Nason MC, Meier-Schellersheim M, Donahue RE, Blazar BR, Dunbar CE, Douek DC. Keratinocyte growth factor increases thymic output of naïve T cells after myeloablative total body irradiation and autologous peripheral blood progenitor cell transplantation in rhesus macaques. Blood 110:441 9, 2007
Panoskaltsis-Mortari A, Price A, Tram K, Wendt C, Blazar BR. A new model for obliterative bronchiolitis post-bone marrow transplant. American journal of respiratory and critical care medicine 176: 713-23, 2007
Wang, H, Gryzwacz B, Sukovich D, McCullar V, Lee AB, Blazar BR, Cornfield D, Miller JS, Verneris MR. The Unexpected Effect of Cyclosporin A on CD56+CD16- and CD56+CD16+ Natural Killer Cell Subpopulations. Blood 110: 1530-9, 2007
Flynn C, Hirsch B, DeFor T, Barker JN, Miller JS, Wagner JE, Blazar BR, Burns LJ, MacMillan ML, Arora M, Weisdorf D. Reduced Intensity Compared to High Dose Conditioning for Allotransplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome: a Comparative Clinical Analysis. Amer J. Hematol. 82: 867-72, 2007
Sharma MD, Baban B, Chandler P, Hou D-Y, Singh N, Yagita H, Azuma M, Blazar BR, Mellor AL, Munn DH: Dendritic cells from tumor-draining lymph nodes directly activate regulatory T cells via indoleamine 2,3-dioxygenase. J. Clin. Invest. 117: 2570-82, 2007
Tomblyn M, Burns L, Blazar BR, Wagner J, Lee C, Rogers T, McGlave P, Miller JS, Weisdorf DJ. Difficult stem cell mobilization despite adequate CD34+ Cell dose predicts shortened progression free and overall survival after autologous HSCT for lymphoma. Bone Marrow Transplant 40: 111-8, 2007
Brunstein C, Barker JN, Weisdorf DJ, DeFor TE, Miller JS, Blazar BR, McGlave PB, Wagner JE: Umbilical Cord Blood Transplantation after a Nonmyeloablative conditioning:Impact on Transplant Outcomes in 110 Adults with Hematological Disease. Blood 110: 3064-70, 2007
Miller JS, Weisdorf D, Burns LJ, SlungaardA, Wagner JE, Verneris MR, Cooley S, Wangen R, Fautsch SK, Nicklow R, DeFor T, Blazar BR. Lymphodepletion followed by donor lymphocyte infusions (DLI) causes significantly more acute graft versus host disease than DLI alone. Blood 110: 2761-3. 2007
Taylor PA, Ehrhardt MJ, Lees CJ, Tolar J, Weigel BJ, Panoskaltsis-Mortari A, Serody JS, Brinkmann V, Blazar BR. Insights into the Mechanism of FTY720 and Compatibility with Regulatory T Cells for the Inhibition of Graft-versus-Host Disease (GVHD). Blood 110: 3480- 88, 2007.
Ghosh A, Wolenski M, Klein C, Welte K, Blazar BR, Sauer MG. Ex vivo generation of Leukemia-specific cytotoxic T cells for adoptive immunotherapy by combining a specific priming step with non specific large- scale expansion. J. Immunotherapy (in press), 2007
Tanaka K, Albin MJ, Yuan X, Yamaura K, Habicht A, Murayama T, Grimm M, Waaga AM, Ueno T, Padera RF, Yagita H, Azuma M, Shin T, Blazar BR, Rothstein DM, Sayegh MH, Najafian N. PDL1 is required for peripheral transplantation tolerance and protection from chronic rejection. J. Immunol. 179: 5204-10, 2007
Habicht A, Kewalaramani R, Vu MD, Demirci G, Blazar BR, Sayegh MH, Li XC. Striking dichotomy of PD-L1 and PD-L2 pathways in regulating alloreactive CD4+ and CD8+ T cells in vivo. Amer. J. Transplant. 7: 2683-92, 2007
Guimond M, Leonard WJ, Spolski R, Rossi SW, Veenstra TG, Hollander GA, Mackall CL, Blazar BR : The thymopoietic effect of keratinocyte growth factor (KGF) requires interleukin-7 and not thymic stromal lymphopoietin (TSLP). Blood (in press), 2007
Jasperson LK, Panoskaltsis-Mortari A, Taylor PA, Bucher C, Mellor AL, Munn DH, Blazar BR. Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease (GVHD) lethality. Blood (in press), 2007
Alderson KL, Zhou Q, Berner V, Wilkins DEC, Weiss JM, Blazar BR, Welniak LA, WIltrout RH, Redelman D, Murphy WJ. Regulatory and Conventional CD4+ T cells Show Differential Effects Correlating with PD-1 and B7-H1 Expression After Immunotherapy. J. Immunol. (in press), 2007
Huang X, Guo H, Kang J, Choi S, Zhou TC, Tammana S, Milone M, Levine BL, June CH, McIvor RS, Wagner JE, Blazar BR, Zhou X, Sleeping Beauty transposon mediated engineering of human primary T cells for the therapy of CD19+ lympho malignancies. Molecular Therapy (in press), 2007
|
